Thursday, July 29

Chilean Sinovac trial leaders recommend third dose of COVID-19 vaccine

Article content

SANTIAGO — The leaders of the Chilean late-stage human trial of the CoronaVac COVID-19 vaccine developed by Chinese pharmaceutical firm Sinovac on Thursday showed a third dose of the jab, saying studies of participants their protecting antibody levels were lower after six months.

The trial leaders said that an in vitro trial to determine the vaccine’s effectiveness against the more contagious Delta strain of the virus showed a four-fold reduction in neutralizing effect against it, compared to a less severe, three-fold reduction previously reported by Chinese scientists . (Reporting by Aislinn Laing; Editing by Leslie Adler)

Leave a Reply

Your email address will not be published. Required fields are marked *